
Switching AATD Patients to Every 3-4 Week Infusions: Logistics and Cost
Patients may embrace less frequent infusions, yet the relationship with a home infusion nurse can decide whether they switch. Infusion centers, home infusion providers, and payers face uncertain operational and pricing effects.
Episodes in this series

In "Switching AATD Patients to Every 3-4 Week Infusions: Logistics and Cost," Dr. Sandhaus shares survey findings and considers what a shift away from weekly dosing means for infrastructure.
Dr. Sandhaus describes a questionnaire that AlphaNet sent to its roughly 8,000 prescribers. It outlined, in general terms, the characteristics of efdoralprin alpha, including infusions every three to four weeks and the blood levels achieved. The survey asked whether respondents would switch from their current IV plasma-derived augmentation therapy. He expected an almost unanimous yes. Instead, the biggest question that came back was whether patients could keep their nurse. If they could not keep the nurse who had come to their home every week for years, patients would hesitate to switch.
Dr. Haumschild calls this a real example and points out that dosing every three to four weeks has implications for site of care, home infusion, and infusion center planning and capacity. He asks Dr. Sandhaus how health systems and payers should think about infrastructure and reimbursement if patients move from weekly to monthly cycles.
Dr. Sandhaus says this is hard to predict. Infusion duration may be longer or not, depending on the approval data. He notes that many patients already infuse faster than the package insert specifies. His center has patients he calls turbo patients, who gradually increased their infusion rates and now tolerate faster infusions. For that reason, he does not think duration will matter much.
Less frequent infusions would free time and space at infusion centers, although he wonders whether other patients would fill those slots. He doubts centers are currently turning patients away. Most patients with AATD in the United States infuse at home, so fewer nurse visits would likely reduce costs for nursing providers.
Pricing is even harder to predict. He notes that production cost does not drive drug pricing. Commercial teams decide what the market will bear, and he expects the therapy will not cost less than current treatment.
In "AATD Pipeline: Replacement, Liver-Directed, RNA, and Gene Therapy Approaches," Dr. Barjaktarevic maps the wider development landscape, from higher-dose and subcutaneous options to RNA-based and gene-based approaches.
Related to this article








